{"id":"https://openalex.org/W3204040372","doi":"https://doi.org/10.1016/j.annonc.2021.08.1164","title":"721O Relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel improves progression-free survival in patients with recurrent platinum-resistant ovarian cancer: A 3-arm, randomized, open-label, phase II study","display_name":"721O Relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel improves progression-free survival in patients with recurrent platinum-resistant ovarian cancer: A 3-arm, randomized, open-label, phase II study","publication_year":2021,"publication_date":"2021-09-01","ids":{"openalex":"https://openalex.org/W3204040372","doi":"https://doi.org/10.1016/j.annonc.2021.08.1164","mag":"3204040372"},"language":"en","primary_location":{"id":"doi:10.1016/j.annonc.2021.08.1164","doi":"https://doi.org/10.1016/j.annonc.2021.08.1164","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2021.08.1164","pdf_url":null,"source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://doi.org/10.1016/j.annonc.2021.08.1164","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111683859","display_name":"Nicola Colombo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I6141010","display_name":"European Institute of Oncology","ror":"https://ror.org/02vr0ne26","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I6141010"]},{"id":"https://openalex.org/I66752286","display_name":"University of Milano-Bicocca","ror":"https://ror.org/01ynf4891","country_code":"IT","type":"education","lineage":["https://openalex.org/I66752286"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"N. Colombo","raw_affiliation_strings":["Department of Gynecologic Oncology, University of Milan-Bicocca, European Institute of Oncology IRCCS, Milan, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Gynecologic Oncology, University of Milan-Bicocca, European Institute of Oncology IRCCS, Milan, Italy","institution_ids":["https://openalex.org/I6141010","https://openalex.org/I66752286"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081690282","display_name":"Dorothy Nguyen","orcid":"https://orcid.org/0000-0002-2570-3023","observed_orcids":["https://orcid.org/0000-0002-2570-3023"]},"institutions":[{"id":"https://openalex.org/I4210132782","display_name":"Corcept Therapeutics (United States)","ror":"https://ror.org/03ey3qt70","country_code":"US","type":"company","lineage":["https://openalex.org/I4210132782"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D.D. Nguyen","raw_affiliation_strings":["Clinical Development, Corcept Therapeutics, Menlo Park, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Development, Corcept Therapeutics, Menlo Park, CA, USA","institution_ids":["https://openalex.org/I4210132782"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046031005","display_name":"Gini F. Fleming","orcid":"https://orcid.org/0000-0003-2845-4023","observed_orcids":["https://orcid.org/0000-0003-2845-4023"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]},{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G.F. Fleming","raw_affiliation_strings":["Hematology/Oncology, University of Chicago Department of Medicine, Chicago, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology/Oncology, University of Chicago Department of Medicine, Chicago, IL, USA","institution_ids":["https://openalex.org/I40347166","https://openalex.org/I4210087865"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029200876","display_name":"Rachel Nicole Grisham","orcid":"https://orcid.org/0000-0002-8631-9324","observed_orcids":["https://orcid.org/0000-0002-8631-9324"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R.N. Grisham","raw_affiliation_strings":["Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY, USA","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061939825","display_name":"Domenica Lorusso","orcid":"https://orcid.org/0000-0003-0981-0598","observed_orcids":["https://orcid.org/0000-0003-0981-0598"]},"institutions":[{"id":"https://openalex.org/I2802557943","display_name":"Agostino Gemelli University Polyclinic","ror":"https://ror.org/00rg70c39","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I2802557943"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"D. Lorusso","raw_affiliation_strings":["Gynaecology Oncology Unit, Fondazione Policlinico Universitario Gemelli, Rome, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gynaecology Oncology Unit, Fondazione Policlinico Universitario Gemelli, Rome, Italy","institution_ids":["https://openalex.org/I2802557943"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080757346","display_name":"Toon Van Gorp","orcid":"https://orcid.org/0000-0002-2564-721X","observed_orcids":["https://orcid.org/0000-0002-2564-721X","https://orcid.org/0000-0002-1573-8716"]},"institutions":[{"id":"https://openalex.org/I2800231306","display_name":"Universitair Ziekenhuis Leuven","ror":"https://ror.org/0424bsv16","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2800231306"]},{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"T. Van Gorp","raw_affiliation_strings":["Department of Gynaecology - Division of Gynaecological Oncology, University Hospitals Leuven / Leuven Cancer Institute, Leuven, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Gynaecology - Division of Gynaecological Oncology, University Hospitals Leuven / Leuven Cancer Institute, Leuven, Belgium","institution_ids":["https://openalex.org/I2800231306","https://openalex.org/I99464096"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067053417","display_name":"Ana Oaknin","orcid":"https://orcid.org/0000-0002-3592-7194","observed_orcids":["https://orcid.org/0000-0002-3592-7194"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]},{"id":"https://openalex.org/I4387155398","display_name":"Vall d'Hebron Institute of Oncology","ror":"https://ror.org/054xx3904","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4387153040","https://openalex.org/I4387155398"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"A. Oaknin","raw_affiliation_strings":["Medical Oncology Dept., Vall d`Hebron University Hospital Institut d'Oncologia, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Dept., Vall d`Hebron University Hospital Institut d'Oncologia, Barcelona, Spain","institution_ids":["https://openalex.org/I4210127641","https://openalex.org/I4387155398"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048748297","display_name":"Hristina I. Pashova","orcid":"https://orcid.org/0000-0003-2297-1652","observed_orcids":["https://orcid.org/0000-0003-2297-1652"]},"institutions":[{"id":"https://openalex.org/I4210132782","display_name":"Corcept Therapeutics (United States)","ror":"https://ror.org/03ey3qt70","country_code":"US","type":"company","lineage":["https://openalex.org/I4210132782"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H.I. Pashova","raw_affiliation_strings":["Biostatistics, Corcept Therapeutics, Menlo Park, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biostatistics, Corcept Therapeutics, Menlo Park, CA, USA","institution_ids":["https://openalex.org/I4210132782"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5008203290","display_name":"Andreas Grauer","orcid":"https://orcid.org/0000-0001-5098-8262","observed_orcids":["https://orcid.org/0000-0001-5098-8262"]},"institutions":[{"id":"https://openalex.org/I4210132782","display_name":"Corcept Therapeutics (United States)","ror":"https://ror.org/03ey3qt70","country_code":"US","type":"company","lineage":["https://openalex.org/I4210132782"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Grauer","raw_affiliation_strings":["Clinical Development, Corcept Therapeutics, Menlo Park, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Development, Corcept Therapeutics, Menlo Park, CA, USA","institution_ids":["https://openalex.org/I4210132782"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":11,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5080,"currency":"USD","value_usd":5080},"apc_paid":null,"fwci":1.1982,"has_fulltext":false,"cited_by_count":12,"citation_normalized_percentile":{"value":0.80616468,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":98},"biblio":{"volume":"32","issue":null,"first_page":"S725","last_page":"S725"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10390","display_name":"Ovarian function and disorders","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2743","display_name":"Reproductive Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/relacorilant","display_name":"relacorilant","score":0.9980000257492065},{"id":"https://openalex.org/keywords/glucocorticoid-receptor-modulators","display_name":"glucocorticoid receptor modulators","score":0.8379999995231628},{"id":"https://openalex.org/keywords/glucocorticoid-receptor-antagonism","display_name":"glucocorticoid receptor antagonism","score":0.8690000176429749},{"id":"https://openalex.org/keywords/nab-paclitaxel","display_name":"nab-paclitaxel","score":0.9729999899864197},{"id":"https://openalex.org/keywords/recurrent-ovarian-cancer","display_name":"recurrent ovarian cancer","score":0.8209999799728394},{"id":"https://openalex.org/keywords/platinum-resistant-ovarian-cancer","display_name":"platinum-resistant ovarian cancer","score":0.9610000252723694},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9890000224113464},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.5059999823570251},{"id":"https://openalex.org/keywords/drug-repurposing","display_name":"drug repurposing","score":0.5849999785423279}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9005756974220276},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.7324998378753662},{"id":"https://openalex.org/C3019800554","wikidata":"https://www.wikidata.org/wiki/Q3813242","display_name":"Open label","level":3,"score":0.6624412536621094},{"id":"https://openalex.org/C59493245","wikidata":"https://www.wikidata.org/wiki/Q14877410","display_name":"Glucocorticoid receptor","level":3,"score":0.5393914580345154},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5299566388130188},{"id":"https://openalex.org/C2910430875","wikidata":"https://www.wikidata.org/wiki/Q7251413","display_name":"Nab-paclitaxel","level":4,"score":0.5004339218139648},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.4925699830055237},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4743936061859131},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.4434436559677124},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.36414843797683716},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3522239923477173},{"id":"https://openalex.org/C2780841215","wikidata":"https://www.wikidata.org/wiki/Q422549","display_name":"Glucocorticoid","level":2,"score":0.34103256464004517},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3023715615272522}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.annonc.2021.08.1164","doi":"https://doi.org/10.1016/j.annonc.2021.08.1164","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2021.08.1164","pdf_url":null,"source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.annonc.2021.08.1164","doi":"https://doi.org/10.1016/j.annonc.2021.08.1164","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2021.08.1164","pdf_url":null,"source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9922999739646912,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4403250934","https://openalex.org/W4410954797","https://openalex.org/W4411026891","https://openalex.org/W7153010564","https://openalex.org/W4411628399","https://openalex.org/W7155409901","https://openalex.org/W4293083621","https://openalex.org/W4382049834","https://openalex.org/W4295820889","https://openalex.org/W4295817237"],"abstract_inverted_index":null,"counts_by_year":[{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":4}],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2021-10-11T00:00:00"}